Blockchain Registration Transaction Record

HeartBeam Submits Breakthrough Cable-Free ECG Tech to FDA

HeartBeam submits 12-lead ECG synthesis software to FDA for 510(k) clearance. Breakthrough cable-free technology aims to transform atrial fibrillation detection and cardiac arrhythmia assessment worldwide.

This development matters because atrial fibrillation affects millions of adults worldwide and is a leading cause of stroke and other serious cardiovascular complications. Current ECG technology often requires clinical visits and wired equipment, creating barriers to timely detection. HeartBeam's cable-free, FDA-cleared technology could enable more accessible and convenient cardiac monitoring, allowing for earlier detection of dangerous arrhythmias. This innovation has the potential to transform outpatient cardiac care, reduce healthcare costs, and ultimately save lives by catching serious heart conditions before they lead to catastrophic events like strokes or heart failure.